Athenex Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Athenex, Inc.

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX).

On March 1, 2021, Athenex issued a press release reporting its fourth quarter results and disclosing receipt of a complete response letter (“CRL”) from the FDA regarding its new drug application for Oral Paclitaxel Plus Encequidar for the treatment of metastatic breast cancer. In the CRL, the FDA expressed the following:

  • Concerns about safety risks associated with increase in neutropenia-related sequelae;
  • Concerns regarding the primary endpoint assessment conducted by the Blinded Independent Central Review (BICR); and
  • Recommendation that Athenex conduct a new clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S.

Following this news, Athenex’s shares plummeted by $6.64 per share, over 54%, to close at $5.46 per share on March 1, 2021.

If you purchased or otherwise acquired Athenex securities and would like to discuss our investigation, please contact us by emailing or by calling (646) 315-9003.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at If you have any questions about this investigation, your rights, or your interests, please contact:

Donald R. Hall
850 Third Avenue, 14th Floor
New York, New York 10022
(646) 315-9003

Laurence D. King
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.